As of 2025-07-03, the EV/EBITDA ratio of Trillium Therapeutics Inc (TRIL.TO) is -43.36. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TRIL.TO's latest enterprise value is 2,479.48 mil CAD. TRIL.TO's TTM EBITDA according to its financial statements is -57.19 mil CAD. Dividing these 2 quantities gives us the above TRIL.TO EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.0x - 9.5x | 8.8x |
| Forward P/E multiples | 7.0x - 9.5x | 8.8x |
| Fair Price | (3.79) - (5.51) | (5.02) |
| Upside | -116.2% - -123.6% | -121.5% |
| Date | EV/EBITDA |